Vyant Bio Receivables

The latest receivables for VYNT is $320K as of December 2022. That compares with $430K in the prior-year period — down 25.6% year over year. Investors often review this figure alongside Vyant Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, VYNT's receivables moved from $430K to $320K — a 25.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vyant Bio's operating scale or balance-sheet position.

A receivables figure of $320K for VYNT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting VYNT's receivables ($320K), review year-over-year change from $430K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Vyant Bio's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.